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Introduction: Adults with Down syndrome are genetically predisposed to develop Alzheimer’s disease and
accumulate beta-amyloid plaques (Aβ) early in life. While Aβ has been heavily studied in Down syndrome, its
relationship with neurofibrillary tau is less understood. The aim of this study was to evaluate neurofibrillary tau
deposition in individuals with Down syndrome with varying levels of Aβ burden.
Methods: A total of 161 adults with Down syndrome (mean age = 39.2 (8.50) years) and 40 healthy, non-Down
syndrome sibling controls (43.2 (12.6) years) underwent T1w-MRI, [C-11]PiB and [F-18]AV-1451 PET scans.
PET images were converted to units of standardized uptake value ratios (SUVrs). Aβ burden was calculated using
the amyloid load metric (AβL); a measure of global Aβ burden that improves quantification from SUVrs by
suppressing the nonspecific binding signal component and computing the specific Aβ signal from all Aβ-carrying
voxels from the image. Regional tau was assessed using control-standardized AV-1451 SUVr. Controlstandardized SUVrs were compared across Down syndrome groups of Aβ-negative (A-) (AβL < 13.3), sub
threshold A+ (13.3 ≤ AβL < 20) and conventionally A+ (AβL ≥ 20) individuals. The subthreshold A + group was
identified as having significantly higher Aβ burden compared to the A- group, but not high enough to satisfy a
conventional A + classification.
Results: A large-sized association that survived adjustment for chronological age, mental age (assessed using the
Peabody Picture Vocabulary Test), and imaging site was observed between AβL and AV-1451 within each Braak
region (p < .05). The A + group showed significantly higher AV-1451 retention across all Braak regions
compared to the A- and subthreshold A + groups (p < .05). The subthreshold A + group showed significantly
higher AV-1451 retention in Braak regions I-III compared to an age-matched sample from the A- group (p < .05).
Discussion: These results show that even the earliest detectable Aβ accumulation in Down syndrome is accom
panied by elevated tau in the early Braak stage regions. This early detection of tau can help characterize the tau
accumulation phase during preclinical Alzheimer’s disease progression in Down syndrome and suggests that
there may be a relatively narrow window after Aβ accumulation begins to prevent the downstream cascade of
events that leads to Alzheimer’s disease.
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than from a select number of ROIs, providing an estimate of the true
global Aβ burden.
The progression of neurofibrillary tau accumulation and its rela
tionship to Aβ and cognitive decline has been of recent interest. The
emergence of tau PET radiotracers, such as flortaucipir (7-(6-(18F)flu
oropyridin-3-yl)-5H-pyrido[4,3-b]indole, [F-18]AV-1451) (Xia et al.,
2013), allows for an in vivo measurement of the degree and spatial extent
of tau deposition. Early tau PET studies in late-onset Alzheimer’s disease
have shown that the spatial progression of PET-detectable tau tracks
closely with the sequence of progression of tau pathology described in
the classic studies of Braak and Braak (Lowe et al., 2018; Braak and
Braak, 1997), that tau is highly associated with Aβ deposition and
cognitive decline (Brier et al., 2016), and that tau PET can distinguish
different clinical groups in the Alzheimer’s disease continuum (Johnson
et al., 2016). In late-onset Alzheimer’s disease, tau PET has been shown
to be more closely associated than Aβ PET with cognitive decline and
dementia status (Ossenkoppele et al., 2016). However, these studies
primarily focus on evaluation of individuals with high tau burden where
cognitive decline is already present. Less emphasis has been placed on
the detection of tau in early stage, presymptomatic disease where
intervention may be more effective at preventing cognitive decline and
neurodegeneration.
While tau PET has rapidly been adapted for use in late-onset Alz
heimer’s disease research studies, its use in Down syndrome has been
understudied. Tau PET investigations in Down syndrome have demon
strated that increased tau burden is very highly correlated with cogni
tive impairment (Rafii et al., 2017) and that tau deposition in Braak
stage regions III-VI accelerates with increasing Aβ deposition (Tudor
ascu et al., 2020). A recent study in Down syndrome has shown elevated
levels of phospho-tau in cerebrospinal fluid in the fourth decade of life,
directly following increases in Aβ PET (Fortea et al., 2020). Similar to
late-onset Alzheimer’s disease studies, evaluation of tau in Down syn
drome has primarily focused on individuals with high Aβ and tau
burden, with little emphasis on early tau detection. To date, no PET
studies in Down syndrome have focused on detection of early tau in
relation to early Aβ progression.
The Alzheimer’s Biomarker Consortium – Down Syndrome (ABC-DS)
is an ongoing longitudinal study with a large cohort aimed at charac
terizing the progression of Alzheimer’s disease-related biomarker
change in individuals with Down syndrome (Handen et al., 2020). The
objectives of the current study were to assess neurofibrillary tau burden
using AV-1451 PET and to compare Braak regional tau deposition to
global Aβ. Using groups of A− , subthreshold A+ and conventionally A+
individuals with Down syndrome, regional AV-1451 was assessed to
identify the earliest detectable increases in neurofibrillary tau. In an
effort to identify and characterize the earliest detectable changes in PETmeasured neurofibrillary tau and the relationship with Aβ, this investi
gation will expand upon the previous findings from ABC-DS by focusing
on the deposition of neurofibrillary tau in individuals with very low
levels of Aβ burden.

1. Introduction
Adults with Down syndrome are at high risk of developing Alz
heimer’s disease. Down syndrome is characterized by triplication of
chromosome 21, which encodes production of the amyloid precursor
protein (APP) and results in early amyloid-β (Aβ) plaque deposition in
the brain (Oyama et al., 1994; Rumble et al., 1989). There is a sharp
increase in prevalence of Alzheimer’s disease dementia after age 50 in
Down syndrome (Schupf, 2002), with the average age of dementia onset
at 55 years (Strydom et al., 2018). The lifetime risk of developing Alz
heimer’s disease in Down syndrome is over 90% (McCarron et al., 2017,
2014), with a survival time of ~4 years following a dementia diagnosis
(Sinai et al., 2018). Since Alzheimer’s disease is the leading cause of
death in this population (Hithersay et al., 2019), there is motivation to
include individuals with Down syndrome in trials aimed at Alzheimer’s
disease treatment and prevention, and particularly anti-amyloid
interventions.
The progression of Aβ plaques throughout Alzheimer’s disease in
Down syndrome has been studied extensively. Pittsburgh Compound-B
(2-(4′ -[11C]methylaminophenyl)-6-hydroxybenzothiazole, [C-11]PiB)
is a positron emission tomography (PET) radiotracer that is used for
the non-invasive imaging of Aβ plaques in neuronal tissue. Using [C-11]
PiB PET, the earliest region of prominent Aβ retention was identified as
the striatum (Handen et al., 2012). This striatum-first pattern of Aβ
deposition in Down syndrome is consistent with the observations in
individuals with autosomal-dominant Alzheimer’s disease and APP
duplication (Bateman et al., 2012; Klunk et al., 2007; Remes et al., 2008;
Villemagne et al., 2009). Similar to late-onset Alzheimer’s disease,
Down syndrome presents identical patterns of cortical Aβ retention
(Annus et al., 2016; Cole et al., 2017; Hartley et al., 2014; Jennings et al.,
2015; Landt et al., 2011; Lao et al., 2018, 2016; Mak et al., 2019;
Matthews et al., 2016; Rafii et al., 2015, 2017; Sabbagh et al., 2015) and
shows longitudinal increases of ~3–4% per year, however with a wide
variation in the age of Aβ onset (Lao et al., 2017; Tudorascu et al., 2019;
Zammit et al., 2020). In late-onset Alzheimer’s disease, striatal Aβ
retention is observed much later in the disease progression (Hanseeuw
et al., 2018) compared to Down syndrome, indicating that the striatum
can be used as an early marker of Alzheimer’s disease progression in this
population (Cohen et al., 2018). The onset of brain amyloidosis in Down
syndrome occurs some 10 to 15 years earlier than in the non-Down
syndrome general population and the deposition of amyloid plaques is
necessary but not sufficient for onset of cognitive symptoms.
With improvements in PET quantification techniques, emphasis has
been placed on early detection of Aβ, specifically at subthreshold
detection levels where the total Aβ burden would not satisfy a conven
tional Aβ-positive (A+) classification. In late-onset Alzheimer’s disease
studies, subthreshold Aβ change has been linked to early tau change and
worsening cognitive performance (Hanseeuw et al., 2019; Landau et al.,
2018; Leal et al., 2018). To better characterize subthreshold Aβ change
in Down syndrome, our previous work evaluated longitudinal Aβ accu
mulation during the earliest stages of Aβ accumulation. Aβ accumulation
in individuals with Down syndrome at typical subthreshold levels was
found to be similar to Aβ accumulation in individuals with Down syn
drome with moderate to high Aβ burden. Using the longitudinal Aβ data,
a cutoff representing subthreshold A+ was established to distinguish
early Aβ accumulators from Aβ-negative (A− ) non-accumulators given
just a single PET scan (Zammit et al., 2021). The classification of sub
threshold A+ was leveraged using longitudinal evaluation with the
amyloid load metric (AβL). The AβL metric is similar to Centiloids and at
the cross-sectional level both measures are highly correlated, but AβL
shows improved longitudinal stability due to its suppression of the
nonspecific binding signal component of PET images (Whittington and
Gunn, 2018). Because of this, abnormal increases in Aβ for A- in
dividuals can be measured more accurately, allowing for the determi
nation of a subthreshold A+ cutoff (Zammit et al., 2021). In addition,
AβL obtains information from all Aβ-carrying voxels in the brain rather

2. Materials and Methods
2.1. Participants
The current sample included 161 adults with Down syndrome (mean
age (SD) = 39.2 (8.50) years) recruited by the University of WisconsinMadison, University of Pittsburgh, University of Cambridge, and Barrow
Neurological Institute sites of the ABC-DS study (Handen et al., 2020).
Institutional Review Board approval and informed consent were ob
tained during enrollment into the study by the participant or legally
designated caregiver according to the Declaration of Helsinki. Inclusion
criteria involved being aged ≥ 25 years and having a receptive language
mental age of at least three years, based upon the Peabody Picture Vo
cabulary Test Fourth Edition (PPVT) (Dunn and Dunn, 2007). Genetic
testing was performed to confirm Down syndrome (trisomy 21,
2
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mosaicism, or partial translocation). Exclusion criteria included having
an unstable psychiatric condition (e.g. untreated) that impaired cogni
tive functioning or a medical condition that was contraindicative of
brain imaging scans (e.g. metallic implants). In the current study, eight
participants were classified having Alzheimer’s disease, eight were
classified having mild cognitive impairment, 137 were cognitively sta
ble, and the remaining eight showed cognitive decline but possibly due
to non-Alzheimer’s disease reasons (e.g., life stressors or medical con
ditions). Determination of cognitively stable status was based on
consensus process that involved review of caregiver-reported and
directly-administered measures of cognition and adaptive behavior and
was made in consideration of premorbid intellectual disability level,
psychiatric and medical conditions and major life events (Hartley et al.,
2020). These diagnostic classifications were performed independent of
imaging findings and based on case consensus processing informed by
directly administered and caregiver-reported measures as previously
described (Handen et al., 2020). Participant demographics are outlined
in Table 1.
Additionally, 40 sibling controls (43.2 (12.6) years) without Down
syndrome were enrolled in the study to act as a biomarker reference
group. The control group was age-matched to the participants with
Down syndrome and were determined to be free of symptoms of de
mentia based on the Montreal Cognitive Assessment (Nasreddine et al.,
2005) and the Eight-Item Interview to Differentiate Aging and Dementia
(Galvin et al., 2005, 2006). The control group underwent the same im
aging protocols as the participants with Down syndrome but were not
administered any additional cognitive testing or neurological
examinations.

to measure neurofibrillary tau acquired 80–100 min post-injection (four
5-minute frames). Using the Statistical Parametric Mapping 12 software
(SPM12), PET frames were re-aligned to correct for motion and averaged
to form a 3D image.
2.4. Aβ PET quantification
PiB PET images were spatially normalized to the Montreal Neuro
logical Institute 152 space (MNI152) via a Down syndrome-specific PET
template for PiB as previously described (Lao et al., 2018). For all im
ages, spatial normalization was required to calculate the amyloid load
(AβL) (Whittington and Gunn, 2018); a global measure of Aβ burden
calculated from the linear least squares method between the PET image
and images of specific and nonspecific PiB binding defined in MNI152
space. Standardized uptake value ratio (SUVr) images were generated by
voxel normalization to cerebellar gray matter, and the global AβL was
calculated following methodology specific to Down syndrome PiB im
ages as previously described (Zammit et al., 2020). Because the striatum
is a region of interest in the monitoring of early Alzheimer’s disease
progression in Down syndrome, striatal PiB SUVr was also calculated for
each participant. Participants were classified as Aβ-negative (A-) for AβL
< 13.3 (Centiloid < 18.0), subthreshold A+ for 13.3 ≤ AβL < 20 (18.0 ≤
Centiloid < 33.3), and conventionally A+ for AβL ≥ 20 (Centiloid ≥
33.3). The conventional A+ cutoff was derived in Down syndrome by
linearly transforming a previously established SUVr/Centiloid cutoff for
A+ into units of AβL (Zammit et al., 2020). The cutoff for subthreshold
A+ was derived from a longitudinal analysis that distinguished early Aβ
accumulators from non-accumulators prior to surpassing the conven
tional A+ cutoff (Zammit et al., 2021). The conversion from AβL to
Centiloids is as follows:

2.2. Sociodemographics

Centiloid = 2.27*AβL − 12.1

Chronological age was coded in years and sex was coded as M/F as
reported by caregivers. The Peabody Picture Vocabulary Test – Fourth
Edition (PPVT) (Dunn and Dunn, 2007) was administered to assess
lifetime cognitive ability. The PPVT has been shown to be a valid
measure of receptive language in adults with Down syndrome that
highly correlates with IQ (Phillips et al., 2014).

2.5. Tau PET quantification
AV-1451 PET images were coregistered to the T1w-MRI for the Down
syndrome and sibling control participants. SUVr images were generated
by voxel normalization to cerebellar gray matter and regional SUVrs
were extracted from Braak regions I-VI (Schöll et al., 2016), with the
exception that the striatum was not included in Braak region V. No
erosion or elimination of regions of focal uptake of AV-1451 was per
formed on the cerebellar gray matter ROI used for signal normalization.
Briefly, the T1w-MRI were processed using FreeSurfer v5.3.0 to delin
eate anatomical ROI masks for multiple brain regions. ROI masks from
FreeSurfer were combined to create Braak stage ROIs, which were used
to calculate the average AV-1451 SUVr within each Braak region. SUVr
images were partial volume corrected using the geometric transfer
matrix (GTM) method (Rousset et al., 1998), which has shown to be an
effective method of reducing spillover effects from the choroid plexus in
AV-1451 images (Baker et al., 2017). Quantification from non-PVC SUVr
images was used for Braak regions III-VI, but due to AV-1451 off-target
binding concerns in the choroid plexus, quantification from GTM-PVC
results was used for Braak regions I-II. The mean SUVr values and
standard deviations were calculated for each Braak region in the sibling
control group and were used to compute a “control-standardized SUVr”
score for the participants with Down syndrome. The controlstandardized SUVr is a type of Z-score, but instead of being standard
ized to the mean and the distribution of the Down syndrome population,
it is standardized to the mean and the distribution of the sibling control
population. This provides the advantage of interpreting these derived
scores in terms of how low/high the Down syndrome group is relative to
the sibling controls. The T1w-MRI were then spatially normalized to the
MNI152 space using SPM12, and the resulting deformation fields were

2.3. Imaging
T1-weighted magnetic resonance imaging (MRI) scans were acquired
on a GE Discovery MR750 (Wisconsin), Siemens Trio or Prisma (Pitts
burgh), GE SIGNA (Cambridge), and GE Discovery MR750 (Barrow).
MRI images were processed using FreeSurfer v5.3.0 for region of interest
(ROI) definition. Positron emission tomography (PET) scans were per
formed on a Siemens ECAT HR + scanner (Wisconsin/Pittsburgh),
Siemens 4-ring Biograph mCT (Pittsburgh), GE SIGNA (Cambridge), and
GE Discovery 710 (Barrow). A target dose of 15 mCi of [C-11]Pittsburgh
Compound-B (PiB) was injected intravenously, and PET scans were used
to measure Aβ acquired 50–70 min post-injection (four 5-minute
frames). Following completion of the PiB scan, a target dose of 10 mCi
of [F-18]AV-1451 was injected intravenously, and PET scans were used
Table 1
Down syndrome participant demographics categorized by Aβ status.

Number of participants
Sex (M/F)
Chronological age (years)
PPVT mental age (years)
Mild cognitive impairment/
Alzheimer’s disease
consensus

All

A-

Subthreshold
A+

A+

161
81/80
39.2
(8.50)
9.83
(3.07)
16

108
52/56
34.9
(5.64)
10.2
(2.90)
1

22
11/11
44.4 (6.32)

31
18/13
50.4
(4.70)
8.49
(3.23)
14

10.0 (3.07)
1

(1)

Because these two metrics are very highly correlated at the crosssectional level, an individual’s group assignment would not change if
Centiloids were used for classification instead of AβL.
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used to spatially normalize the AV-1451 SUVr images.

3. Results

2.6. Statistical analyses

3.1. Global AβL, striatal PiB SUVr and Braak regional AV-1451

All statistical analyses were performed using SAS 9.4. Global AβL and
Braak regional AV-1451 control-standardized SUVrs were compared
using Pearson’s partial correlations while adjusting for age, PPVT, and
imaging site. For Braak regions I-II, the Pearson’s partial correlations
were also adjusted for AV-1451 in the choroid plexus. The Pearson’s
analysis was then repeated to compare striatal PiB SUVr to Braak
regional control-standardized SUVr. AV-1451 control-standardized
SUVrs across all Braak regions were then compared across groups of A-,
subthreshold A+, and A+ individuals with Down syndrome using
analysis of covariance (ANCOVA) while adjusting for age, PPVT and
imaging site. For Braak regions I-II, the ANCOVA analysis also included
AV-1451 in the choroid plexus as a covariate. Individual group com
parisons were then performed by taking the least square differences
between the means while adjusting for multiple comparisons using the
Tukey-Kramer method. Group-averaged AV-1451 images (MNI152
space) were then generated for the A- and subthreshold A+ groups, and
the difference was taken between the images to visualize regional dif
ferences in AV-1451 retention. Because the mean age of the subthresh
old A+ group was ~10 years older than the A- group, an additional
analysis was performed with an age-matched sample of the A- and
subthreshold A+ groups to account for age-related effects. Using an agematched sample of A- and subthreshold A+ Down syndrome, Braak
regional AV-1451 control-standardized SUVrs were compared using
two-tailed Student’s t-tests while adjusting for imaging site. For Braak
regions I-II, all comparisons were made both with and without GTM
correction.

In this cohort, 108 individuals with Down syndrome were classified
as A-, 22 were subthreshold A+, and 31 were conventionally A+.
Representative AV-1451 SUVr images showing elevated binding in each
Braak region are displayed in Fig. 1. Average AV-1451 SUVr images for
the A-, subthreshold A+ and conventionally A+ groups are displayed in
Fig. 2. Fig. 3 displays the AV-1451 control-standardized SUVr with
respect to global AβL for each individual Braak region. Pearson’s partial
correlations (presented as Pearson’s R [95% CI]) revealed significant
positive associations (all p < .0001) with a large magnitude effect size
(Cohen’s d) (Cohen, 1988, 1992) between AβL and AV-1451 in all Braak
regions (Braak I: 0.70 [0.61, 0.77]; Braak II: 0.74 [0.66, 0.81]; Braak III:
0.83 [0.77, 0.87]; Braak IV: 0.79 [0.72, 0.84]; Braak V: 0.81 [0.75,
0.86]; Braak VI: 0.77 [0.70, 0.83]). Following GTM correction, signifi
cant associations between AβL and AV-1451 remained significant in
Braak regions I (0.56 [0.44, 0.66]) and II (0.56 [0.44, 0.66]). Pearson’s
partial correlations were then performed between striatal PiB SUVr and
Braak regional AV-1451. Positive associations were observed between
striatal PiB and AV-1451 in all Braak regions (Braak I: 0.65 [0.55, 0.74];
Braak II: 0.66 [0.56, 0.74]; Braak III: 0.63 [0.52, 0.72]; Braak IV: 0.58
[0.46, 0.68]; Braak V: 0.58 [0.46, 0.68]; Braak VI: 0.51 [0.38, 0.62]).
Following GTM correction, significant associations between striatal PiB
and AV-1451 remained significant in Braak regions I (0.55 [0.42, 0.66])
and II (0.50 [0.37, 0.61]). All associations survived adjustment for age,
PPVT, and imaging site. In addition, the associations for Braak regions III survived adjustment for AV-1451 in the choroid plexus.
3.2. AV-1451 retention relative to Aβ status

2.7. Data availability

From ANCOVA, significant differences in AV-1451 control-stan
dardized SUVr were observed between the A-, subthreshold A+, and A+
groups for Braak regions I (F(df) = 23.4(6), p < .0001), II (F(df) = 40.4
(6), p < .0001), III (F(df) = 32.8(5), p < .0001), IV (F(df) = 22.7(5), p <
.0001), V (F(df) = 17.9(5), p < .0001), and VI (F(df) = 10.6(5), p <
.0001). Additionally, significant differences were observed following

The imaging sites have entered web-based data through the Alz
heimer’s Therapeutic Research Institute (ATRI) as part of the ABC-DS
study. Data from the ABC-DS study and research methodology is
currently available to the scientific community through the LONI
database.

Fig. 1. Representative AV-1451 images for individuals with Down syndrome across each Braak stage, and for the sibling controls.
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Fig. 2. Average AV-1451 SUVr images for groups of A-, subthreshold A+ and conventionally A+ individuals with Down syndrome.

GTM correction in Braak regions I (F(df) = 14.8(6), p < .0001) and II (F
(df) = 24.7(6), p < .0001). All associations survived adjustment for age,
PPVT and imaging site. The associations for Braak regions I-II also sur
vived adjustment for AV-1451 in the choroid plexus. From the individ
ual group comparisons, least square differences between the means
(with 95% CIs) for all Braak regions are displayed in Table 2. The A+
group showed significantly higher AV-1451 control-standardized SUVrs
relative to the A- and the subthreshold A+ groups across Braak regions IVI (all p < .0001 adjusted for multiple comparisons). The subthreshold
A+ group showed significantly higher AV-1451 control-standardized
SUVrs compared to the A- group in Braak regions I (adjusted p = .0021)
and II (adjusted p = .0031) without GTM correction, and in Braak re
gions I (adjusted p < .0001) and II (adjusted p = .0001) with GTM
correction. The subthreshold A+ group did not differ from the A- group
in Braak regions III-VI (all p > .05 adjusted for multiple comparisons).

more feasible compared to those at risk for late-onset Alzheimer’s dis
ease development. Our previous work in this population evaluated the
longitudinal spread of Aβ (Zammit et al., 2021, 2020; Lao et al., 2017;
Tudorascu et al., 2019), neurofibrillary tau deposition (Tudorascu et al.,
2020), glucose hypometabolism (Lao et al., 2018; Zammit et al., 2020)
and cognitive decline (Hartley et al., 2020) in order to characterize these
biomarkers within the amyloid/tau/neurodegeneration (AT(N)) frame
work of Alzheimer’s disease (Jack et al., 2016; Rafii et al., 2020). The
current work builds upon these previous findings by evaluating neuro
fibrillary tau deposition during the earliest stages of Aβ accumulation in
order to better characterize early tau progression. With a better char
acterization of early tau in relation to Aβ, clinical trial studies can utilize
tau PET to evaluate whether an anti-amyloid therapy is effective at
preventing tau progression, especially that tau is more strongly corre
lated with cognitive decline.
Using AV-1451 PET, we have shown that Braak regional tau in Down
syndrome is highly associated with global Aβ burden measured using
AβL. The greatest associations between Aβ and tau were observed in
Braak regions III-VI. In the A+ group, AV-1451 retention appeared to
plateau with increased Aβ in Braak regions I-II, whereas Braak regions
III-VI showed significantly increased tau burden. The lack of significant
tau increase with Aβ in these early Braak regions is not unique to Down
syndrome, as Braak I-II tau also appears to plateau while cortical regions
continue to escalate in late-onset Alzheimer’s disease (Jack et al., 2019;
Schwarz et al., 2016). This may indicate that the associations between
Aβ and tau in these early Braak regions are primarily driven by in
dividuals with low to moderate Aβ burden, and that the positive asso
ciation between biomarkers diminishes with higher Aβ levels. In a study
of autosomal dominant Alzheimer’s disease, striatal PiB showed greater
associations with tau compared to cortical PiB (Hanseeuw et al., 2019),
and it is suggested that striatal PiB may also be highly associated with
regional tau spread in Down syndrome. To evaluate this, Pearson’s
partial correlations were performed between striatal PiB SUVr and Braak
regional AV-1451 in our Down syndrome cohort. Striatal PiB SUVr was
highly associated with Braak regional tau, however, the effect sizes were
not as large when compared to global AβL. The large effect sizes
observed with AβL are likely a result of the improved sensitivity this
metric provides to detect Aβ when compared to SUVr. Our previous
work in Down syndrome reported significant associations between
increased Aβ burden and cognition as well as associations between
glucose hypometabolism and cognition (Zammit et al., 2020), and work
is currently ongoing to evaluate the association of tau (treated as a
continuous variable) across a range of cognitive domains.
While tau in Braak regions I-II had significant associations with Aβ,

3.3. Age-matched comparison between AV-1451 retention for A- and
subthreshold A+ groups
The SUVr difference image between the subthreshold A+ groupaveraged and A- group-averaged AV-1451 images revealed higher
retention in Braak regions I-III for the subthreshold A+ group (Fig. 4).
Similarly, the SUVr difference image for age-matched samples of these
groups revealed the same pattern of higher AV-1451 retention in Braak
regions I-III in the subthreshold A+ group (Fig. 4). Using an agematched sample of A- (n = 72) and subthreshold A+ (n = 22) in
dividuals with Down syndrome, a Student’s t-test analysis was per
formed to compare Braak regional AV-1451 retention between groups.
AV-1451 control-standardized SUVrs were significantly higher in
Braak regions I-III (all p < .05) for the subthreshold A+ group, and no
significant difference was observed in Braak regions IV-VI between
groups (Table 3). Imaging site did not influence the model outcome.
3.4. Discussion
Due to the similarities in Alzheimer’s disease biomarker progression
between Down syndrome and late-onset Alzheimer’s disease, Down
syndrome can serve as a model population for trials aimed at Alz
heimer’s disease prevention, such as those involving anti-amyloid
treatments. Since the Down syndrome population is uniformly affected
by Alzheimer’s disease pathology during the fourth decade of life and
progression of Alzheimer’s disease biomarkers follow a predictable time
course, recruitment of these individuals into projects such as the TrialReady Cohort – Down Syndrome (TRC-DS) study (Rafii et al., 2020) is
5
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Fig. 3. Braak regional AV-1451 control-standardized SUVr with respect to global AβL for A-, subthreshold A+, and A+ Down syndrome.

the quantification of tau in these regions was likely influenced by signal
spillover from off-target AV-1451 binding in the choroid plexus (Lois
et al., 2019). To account for choroid plexus spillover, the geometric
transfer matrix (GTM) method of partial volume correction was per
formed on Braak regions I-II. Following GTM correction, the associations
between Aβ and tau remained significant in these regions. Due to offtarget binding of AV-1451 in the basal ganglia, the striatum was
excluded from Braak region V in these analyses. The voxel analysis
evaluating SUVr difference images between subthreshold A+ and A−
groups did reveal elevated striatal AV-1451 retention in the subthresh
old A+ group, but when compared to an age-matched sample of A- in
dividuals with Down syndrome, no difference was observed between

striatal retention. This finding indicates that the striatal AV-1451
binding observed in Down syndrome may be age-related, similar to
the patterns of increased AV-1451 retention in healthy controls with age
(Smith et al., 2017). An AV-1451 study in frontotemporal dementia
evaluated the potential of W-score maps (a modified Z-score adjusted for
covariates) relative to a healthy control group to monitor increased
retention while correcting for age-related effects (Tsai et al., 2019). Due
to the association between age and off-target AV-1451 binding in the
striatum, this methodology may be useful to distinguish Alzheimer’s
disease-related increases in striatal AV-1451 retention in Down syn
drome. Because the striatum is a region of early Aβ deposition in Down
syndrome, evaluation of the striatum with a radiotracer free from off6
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the subthreshold Aβ accumulation phase, highlighting the importance of
early detection and intervention of Alzheimer’s disease biomarker pro
gression. The identification of early tau with subthreshold Aβ accumu
lation is not unique to Down syndrome, as both elevated tau and
worsening cognitive performance were accompanied by subthreshold
Aβ in late-onset Alzheimer’s disease (Hanseeuw et al., 2019). Another
study in late-onset Alzheimer’s disease reports that individuals with
subthreshold Aβ had predictable neocortical tau spread within a 5 year
period, followed shortly by cognitive decline (Leal et al., 2018).
Furthermore, memory decline was observed with subthreshold Aβ
accumulation in healthy, older adults at risk for Alzheimer’s disease
(Landau et al., 2018). Due to the similarities between Alzheimer’s dis
ease pathology progression in Down syndrome and late-onset Alz
heimer’s disease, individuals with Down syndrome with a subthreshold
A+ classification should be more carefully evaluated for cognitive
decline.
For this analysis, we chose to quantify tau using control-standardized
SUVrs from the AV-1451 data relative to the sibling control group.
Control-standardized SUVrs were used as this method standardizes the
SUVr by accounting for the regional variance of AV-1451 binding
(Vemuri et al., 2017). Because the control-standardized SUVr is a
method of Z-transforming the AV-1451 data, the associations observed
between groups in this study would be the same as those observed with
non-standardized SUVr. There are benefits to using control-standardized
SUVrs, as this method can facilitate head-to-head comparisons of im
aging studies that utilize different populations and different tau radio
tracers, and they can also be used to generate a standardized cutoff for
tau-positivity (T+) that would theoretically be similar across all tau
PET radiotracers (Villemagne et al., 2020). For the current study,
control-standardized SUVrs provided the sensitivity to identify very
early tau deposition during the subthreshold Aβ accumulation phase,
and lay the groundwork for establishing a T+ cutoff for Down syndrome
within the AT(N) classification scheme (Jack et al., 2016; Rafii et al.,
2020).
Future work in this population will focus on further evaluation of Aβ,
tau, and neurodegeneration throughout Alzheimer’s disease progres
sion. Additionally, cutoffs for T+ in Down syndrome will be explored
and can be validated (Salvadó et al., 2019) against plasma or cerebro
spinal fluid biomarkers of total tau and phospho-tau181 (Handen et al.,
2020) or phospho-tau217 (Mattsson-Carlgren, et al., 2021) that have
been collected as part of ABC-DS. Longitudinal imaging of tau is also
needed to explore tau accumulation across the different stages of Alz
heimer’s disease progression. Comparisons of tau with changes in
cognition will also be performed using established outcome measures of
cognitive decline for Down syndrome (Hartley et al., 2020).

Table 2
Least square differences (with 95% CIs) between the means of Braak regional
AV-1451 control-standardized SUVr for A-, subthreshold A+, and A+ Down
syndrome. Comparisons for Braak regions I-II were made without and with
geometric transfer matrix (GTM) method partial volume correction.
Braak
region

Group 1

Group 2

Least square difference
[95% CI]

Braak I

A−
A−

A+
Subthreshold
A+
A+

− 3.90 [− 4.67, − 3.13]****
− 1.23 [− 2.09, − 0.39]**

A+
Subthreshold
A+
A+

− 3.62 [− 4.30, − 2.94]****
− 1.06 [− 1.82, − 0.31]**

A+

− 3.30 [− 4.20, − 2.40]****

Subthreshold
A+
A+

− 1.64 [− 2.64, − 0.65]***

A+

− 2.11 [− 2.57, − 1.65]****

Subthreshold
A+
A+

− 1.03 [− 1.55, − 0.53]***

A+
Subthreshold
A+
A+

− 6.89 [− 8.08, − 5.69]****
− 0.68 [− 2.00, 0.65]

A+
Subthreshold
A+
A+

− 4.85 [− 5.90, − 3.81]****
− 0.30 [− 1.46, 0.85]

A+
Subthreshold
A+
A+

− 5.44 [− 6.75, − 4.13]****
− 0.27 [− 1.72, 1.18]

A+
Subthreshold
A+
A+

− 4.14 [− 5.49, − 2.79]****
0.17 [− 1.32, 1.67]

Braak II

Braak I
GTM

Braak II
GTM

Braak III

Braak IV

Braak V

Braak VI

Subthreshold
A+
A−
A−
Subthreshold
A+
A−
A−
Subthreshold
A+
A−
A−
Subthreshold
A+
A−
A−
Subthreshold
A+
A−
A−
Subthreshold
A+
A−
A−
Subthreshold
A+
A−
A−
Subthreshold
A+

− 2.66 [− 3.68, − 1.64]****

− 2.56 [− 3.46, − 1.65]****

− 1.65 [− 2.86, − 0.46]**

− 1.07 [− 1.68, − 0.46]***

− 6.21 [− 7.80, − 4.61]****

− 4.55 [− 5.94, − 3.16]****

− 5.17 [− 6.92, − 3.43]****

− 4.31 [− 6.11, − 2.52]****

Significance: * 0.05 ** 0.01 *** 0.001 **** 0.0001 adjusted for multiple com
parisons using the Tukey-Kramer method.

target basal ganglia binding may better characterize tau spread in this
region. Our findings also suggest that the spatial patterns of tau follow
the conventional Braak staging of tau pathology, as elevated tau was not
present within a late Braak region at the individual level without already
being elevated in each antecedent region. These findings are in accor
dance with our previous findings in Down syndrome showing that
higher tau pathology emerges in Braak stage regions as Aβ pathology
increases, and that the associations between Aβ and tau are similar to
late-onset Alzheimer’s disease (Tudorascu et al., 2020).
When evaluating Braak regional tau across groups based on Aβ sta
tus, the conventionally A+ group had significantly higher tau burden in
all Braak regions compared to the subthreshold A+ and A− groups.
Compared to the A- group, the subthreshold A+ group had significantly
higher tau deposition in Braak regions I-II. Because the mean age of the
subthreshold A+ group was ~10 years older than the A- group, an
additional analysis was performed using an age-matched sample from
the A- group to account for age-related effects. Given the age-matched
samples, tau burden in Braak regions I-III was significantly higher in
the subthreshold A+ group compared to the A- group, suggesting that Aβ
status rather than age is a better indicator of tau presence. These findings
suggest that tau deposition in Down syndrome can be detected during

3.5. Conclusion
Evaluating PiB and AV-1451 PET in a large Down syndrome popu
lation revealed significant associations between Aβ deposition and
Braak-regional tau deposition. The A+ Down syndrome group showed
higher tau burden in Braak regions I-VI compared to the subthreshold
A+ and A− Down syndrome groups. The subthreshold A+ group showed
significantly higher tau burden in Braak regions I-III compared to an agematched subset of the A− group, suggesting that tau deposition begins
very early in the preclinical Alzheimer’s disease phase.
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Braak region

A-

Subthreshold A+

P-value

Braak I
Braak II
Braak I GTM
Braak II GTM
Braak III
Braak IV
Braak V
Braak VI

0.085 (1.20)
0.048 (0.86)
0.23 (1.72)
0.18 (0.75)
− 0.033 (0.92)
− 0.13 (0.81)
− 0.15 (0.85)
− 0.15 (0.86)

1.12 (1.52)
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1.23 (2.13)
1.10 (1.52)
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− 0.39 (0.89)

0.0013
0.0007
0.027
0.0002
0.030
0.61
0.64
0.30
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Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive
supranuclear palsy. Mov Disord 32, 108–114. https://doi.org/10.1002/mds.26813.
Tsai, R.M., Bejanin, A., Lesman-Segev, O., LaJoie, R., Visani, A., Bourakova, V., et al.,
2019. 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes.
Alz Res Therapy 11, 13. https://doi.org/10.1186/s13195-019-0470-7.
Vemuri, P., Lowe, V.J., Knopman, D.S., Senjem, M.L., Kemp, B.J., Schwarz, C.G., et al.,
2017. Tau-PET uptake: Regional variation in average SUVR and impact of amyloid
deposition. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 6,
21–30. https://doi.org/10.1016/j.dadm.2016.12.010.
Villemagne, V.L., Lopresti, B.J., Dore, V., Tudorascu, D., Ikonomovic, M.D., Burnham, S.,
et al., 2020. What is T+? A Gordian Knot of Tracers, Thresholds & Topographies.
Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.120.245423.
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